文献速递泌尿生殖MR

基于PI-RADS第2版的活检前双参数MRI检测临床显著前列腺癌:一项多中心研究

Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
PubMed 文献 · AJR Am J Roentgenol · 2019-02-19

这项在两家机构开展的回顾性研究纳入113例接受根治性前列腺切除术且术前完成3T多参数MRI的前列腺癌患者,由两名独立放射科医师用PI-RADSv2对双参数MRI(无DCE-MRI)与多参数MRI(含DCE-MRI)评分。临床显著癌检出率为74.3%(84/113),双参数MRI与多参数MRI在任何PI-RADS评分下的检出率均无统计学差异(p > 0.05)。结论认为活检前双参数MRI检测临床显著癌的诊断性能与含DCE-MRI的多参数MRI相似。

要点

  • 临床显著癌占74.3%(84/113),双参数MRI与多参数MRI各PI-RADS评分检出率均无统计学差异(p > 0.05)。
  • 外周带病灶中,阅片者1将22个、阅片者2将13个PI-RADS 3分病灶在加做DCE-MRI后升级为PI-RADS 4分(3+1)。
  • PI-RADS评分者间一致性为中等:双参数MRI κ = 0.540,多参数MRI κ = 0.478。

核心结论

  • 对于临床显著癌检测,活检前不含DCE-MRI的双参数MRI诊断性能与含DCE-MRI的多参数MRI相似。

研究设计与样本

  • 在两家机构开展的回顾性研究,纳入113例接受根治性前列腺切除术且术前完成3T多参数MRI(含T2加权成像、DWI和DCE-MRI)的前列腺癌患者,由两名独立放射科医师使用PI-RADSv2对全部患者可疑病灶评分。

关键影像表现/征象

  • 临床显著癌在74.3%(84/113)的患者中被识别。
  • 外周带病灶中,阅片者1将22个、阅片者2将13个病灶从双参数MRI的PI-RADS 3分升级为多参数MRI的PI-RADS 4分(3+1)。
  • 多参数MRI上PI-RADS 3+1病灶的临床显著癌检出率为阅片者1 63.6%、阅片者2 69.2%,略高于双参数MRI上PI-RADS 3病灶的阅片者1 53.8%、阅片者2 60.0%,但差异无统计学意义(p > 0.05)。

诊断标准与关键数值

  • 以根治性前列腺切除术后病理为参考,临床显著癌检出率在双参数MRI与多参数MRI之间任何PI-RADS评分下均无统计学差异(p > 0.05)。
  • 外周带病灶由双参数MRI PI-RADS 3分升级为多参数MRI PI-RADS 4分(3+1)后,临床显著癌检出率:阅片者1 63.6% vs 53.8%,阅片者2 69.2% vs 60.0%,差异均无统计学意义(p > 0.05)。
  • PI-RADS评分者间一致性:双参数MRI κ = 0.540,多参数MRI κ = 0.478,均为中等一致性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study was to evaluate the diagnostic performance of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) with respect to prebiopsy MRI with and without dynamic contrast enhancement in the detection of clinically significant cancer (CSC).

MATERIALS AND METHODS: A total of 113 patients with prostate cancer who underwent radical prostatectomy and prebiopsy multiparametric 3-T MRI (mpMRI) that included T2-weighted imaging, DWI, and dynamic contrast-enhanced MRI (DCE-MRI) were enrolled in a retrospective study conducted at two institutions. For detecting CSC at prebiopsy mpMRI with DCE-MRI and biparametric MRI (bpMRI) without DCE-MRI, two independent radiologists using PI-RADSv2 scored suspicious lesions in all patients.

RESULTS: CSC was identified in 74.3% (84/113) of patients. For CSC detection rate, no statistical differences between bpMRI and mpMRI were found for any PI-RADS score (p > 0.05). For cancer in the peripheral zone, reader 1 upgraded 22 lesions and reader 2 upgraded 13 lesions from PI-RADS score 3 at bpMRI to PI-RADS 4 (3 + 1) at mpMRI. The CSC detection rate of PI-RADS 3 + 1 lesions at mpMRI (reader 1, 63.6%; reader 2, 69.2%) was slightly greater than that of PI-RADS 3 lesions at bpMRI (reader 1, 53.8%; reader 2, 60.0%), which was not statistically different (p > 0.05). Interreader agreement on PI-RADS scoring was moderate for both bpMRI (κ = 0.540) and mpMRI (κ = 0.478).

CONCLUSION: For detecting CSC, the diagnostic performance of prebiopsy bpMRI without DCE-MRI is similar to that of mpMRI with DCE-MRI.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Choi MH, Kim CK, Lee YJ, et al. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study. AJR Am J Roentgenol. 2019. PMID: 30779662. doi:10.2214/AJR.18.20498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。